share_log

Marker Therapeutics Shares Are Trading Lower. The Company Reported Results From Its Phase 1 APOLLO Study of MT-601 in Relapsed Lymphoma.

Benzinga ·  05:57
Marker Therapeutics Shares Are Trading Lower. The Company Reported Results From Its Phase 1 APOLLO Study of MT-601 in Relapsed Lymphoma.
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment